ClinicalTrials.gg
CompletedNCT03639675VENERAUpdated Mar 3, 2020Results posted

Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied

A Phase 3 interventional study of Aflibercept (EYLEA, BAY86-5321) and Topical IOP-lowering drugs in Glaucoma, Neovascular, sponsored by Bayer. Completed at 7 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-03-03.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

The researchers in this trial want to learn how the drug aflibercept works in in Japanese patients with increased eye pressure that is caused by new blood vessels growing in the eye (neovascular glaucoma or NVG). They also want to find out how patient tolerate the application of the drug that is injected in the vitreous humor of the eye and if this will cause any medical problems during the trial (vitreous humor, also called vitreous body is the clear gel that fills the space between the lens and the retina of the eyeball).

02

Conditions studied

  • Glaucoma, Neovascular

Browse trials for

03

In context

Glaucoma, Neovascular

39 studies on the registry are indexed under Glaucoma, Neovascular; 5 are open to participants now.

This study's enrollment of 16 is below the median of 40 across 32 interventional studies indexed under Glaucoma, Neovascular.

Browse Glaucoma, Neovascular studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese men and women aged 20 years or older
  • Patients diagnosed as having NVG (neovascular glaucoma) with neovascularization in the anterior segment (both iris and anterior chamber angle)
  • Patients with IOP (intraocular pressure) higher than 25 mmHg in the study eye due to anterior segment (both iris and anterior chamber angle) neovascularization

Exclusion criteria

Exclusion Criteria:

  • Patients with angle-closure due to conditions other than NVG or complete angle-closure due to NVG
  • Patients with a known or suspected ocular or peri-ocular infection
  • Patients with severe intraocular inflammation in the study eye
  • Women who are pregnant, suspected of being pregnant or lactating
  • Patients with known allergy to aflibercept
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    NVG patients

    Japanese patients with neovascular glaucoma

    Drug: Aflibercept (EYLEA, BAY86-5321) · Drug: Topical IOP-lowering drugs

Interventions

  • 2 mg (0.05 mL), Intravitreal injection (IVT), single dose.

  • DrugTopical IOP-lowering drugs

    A combination of at least 3 topical IOP-lowering drugs will be administered during a run-in phase before treatment and should be kept unchanged until IOP evaluation at Week 1, after which they may be reduced according to the investigator's opinion

06

What researchers measure

Primary outcomes

  1. Change in Intraocular Pressure (IOP) From Baseline to Week 1

    The primary efficacy analysis was on the changes in IOP from baseline to Week 1 (LOCF).

    Time frame: Baseline and week 1

Secondary outcomes

  1. Percentage of Participants Who Had Improved Neovascularization of the Iris (NVI) Grade From Baseline to Week 1

    NVI Grade: 0=No iris neovascularization; 1=Fine surface neovascularization of the pupillary zone of the iris involving less than two quadrants; 2=Surface neovascularization of the pupillary zone of the iris involving more than two quadrants; 3=In addition to neovascularization of the pupillary zone, neovascularization of the ciliary zone of the iris and/or ectropion uveae involving one to three quadrants; 4=In addition to neovascularization of the pupillary zone, neovascularization of the ciliary zone of the iris and/or ectropion uveae involving more than three quadrants. The change in NVI grades categorized to "Improved" means improvement by at least one grade from baseline.

    Time frame: Baseline and week 1

07

Results

Posted Feb 18, 2020

Participant flow

Study was conducted at 7 study sites in Japan from 3-Oct-2018 (first subject's first visit) to 14-Mar-2019 (last subject's last visit).

Participant flow — Overall Study
MilestoneAflibercept 2 mg Intravitreal (IVT) Injection Group
Started16
Received treatment16
Completed15
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryChange in Intraocular Pressure (IOP) From Baseline to Week 1

The primary efficacy analysis was on the changes in IOP from baseline to Week 1 (LOCF).

Time frame:
Baseline and week 1
Reported as:
Mean · mmHg
Change in Intraocular Pressure (IOP) From Baseline to Week 1
mmHgAflibercept 2 mg Intravitreal (IVT) Injection Group
Change in Intraocular Pressure (IOP) From Baseline to Week 1-8.3 ± 7.3
Statistical analysis
  • Aflibercept 2 mg Intravitreal (IVT) Injection Group · one-sample t-statistics · p = 0.0004 · Mean change: -8.3 · 95% CI -12.2 to -4.4
SecondaryPercentage of Participants Who Had Improved Neovascularization of the Iris (NVI) Grade From Baseline to Week 1

NVI Grade: 0=No iris neovascularization; 1=Fine surface neovascularization of the pupillary zone of the iris involving less than two quadrants; 2=Surface neovascularization of the pupillary zone of the iris involving more than two quadrants; 3=In addition to neovascularization of the pupillary zone, neovascularization of the ciliary zone of the iris and/or ectropion uveae involving one to three quadrants; 4=In addition to neovascularization of the pupillary zone, neovascularization of the ciliary zone of the iris and/or ectropion uveae involving more than three quadrants. The change in NVI grades categorized to "Improved" means improvement by at least one grade from baseline.

Time frame:
Baseline and week 1
Reported as:
Count of participants · Participants
Percentage of Participants Who Had Improved Neovascularization of the Iris (NVI) Grade From Baseline to Week 1
ParticipantsAflibercept 2 mg Intravitreal (IVT) Injection Group
Percentage of Participants Who Had Improved Neovascularization of the Iris (NVI) Grade From Baseline to Week 113

Adverse events

Collected over 30 days from administration in each patients. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept 2 mg Intravitreal (IVT) Injection Group0/16 (0%)1/16 (6.3%)6/16 (37.5%)
Most frequent serious events
Most frequent serious events
EventAflibercept 2 mg Intravitreal (IVT) Injection Group
PneumoniaInfections and infestations1/16
Most frequent other events
Most frequent other events
EventAflibercept 2 mg Intravitreal (IVT) Injection Group
Eye painEye disorders4/16
Corneal erosionEye disorders1/16
Eye pruritusEye disorders1/16
NasopharyngitisInfections and infestations1/16
PneumoniaInfections and infestations1/16
HeadacheNervous system disorders1/16

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Aflibercept 2 mg Intravitreal (IVT) Injection Group
Mean65.6 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept 2 mg Intravitreal (IVT) Injection Group
Female4
Male12
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Aflibercept 2 mg Intravitreal (IVT) Injection Group
Hispanic or Latino0
Not Hispanic or Latino16
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Aflibercept 2 mg Intravitreal (IVT) Injection Group
American Indian or Alaska Native0
Asian16
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

7 sites
  • University of Fukui Hospital
    Yoshida, Fukui 910-1193, Japan
  • Tsukazaki Hospital
    Himeji, Hyogo 671-1227, Japan
  • Kanazawa University Hospital
    Kanazawa, Ishikawa 920-8641, Japan
  • St. Marianna University School of Medicine Hospital
    Kawasaki, Kanagawa 216-8511, Japan
  • Osaka University Hospital
    Suita, Osaka 565-0871, Japan
  • Takatsuki Red Cross Hospital
    Takatsuki, Osaka 569-1096, Japan
  • Shimane University Hospital
    Izumo, Shimane 693-8501, Japan
09

References and documents

Publications

  • Inatani M, Higashide T, Matsushita K, Nagasato D, Takagi H, Ueki M, Takai Y, Miyazaki K, Iwamoto Y, Kobayashi M, Leal S. Efficacy and Safety of Intravitreal Aflibercept Injection in Japanese Patients with Neovascular Glaucoma: Outcomes from the VENERA Study. Adv Ther. 2021 Feb;38(2):1106-1115. doi: 10.1007/s12325-020-01580-y. Epub 2020 Dec 16. PubMed 33330959 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Feb 2019, 4 months.

Results were first posted in Feb 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2018
First posted
Aug 21, 2018
StartActual
Oct 3, 2018
Primary completionActual
Feb 14, 2019
CompletionActual
Mar 14, 2019
Results first posted
Feb 18, 2020
Last update
Mar 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03639675
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Aug 21, 2018
Start date
Oct 3, 2018
Primary completion
Feb 14, 2019
Completion
Mar 14, 2019
Results posted
Feb 18, 2020
Last update
Mar 3, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion